2016 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
07/12/16Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
MISSISSAUGA, ON, July 12, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin is a topical treatment proposed for use in adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian commercialization rights to Ozenoxacin from Ferrer International SA ("Ferrer"), a privately-he... 
Printer Friendly Version
07/06/16Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
MISSISSAUGA, ON, July 6, 2016 /PRNewswire/ - A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report (the "EWR") filed on July 5, 2016 by 1207407 Ontario Limited ("1207407"), a company wholly owned by Dr. John D. Mull.  The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address ... 
Printer Friendly Version
06/20/16Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders
MISSISSAUGA, ON, June 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights ... 
Printer Friendly Version
05/31/16Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences
MISSISSAUGA, ON, May 31, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences. Jefferies 2016 Healthcare Conference in New York on June 10 at 8:30 a.m. ET. JMP Securities 2016 Life Sciences Conference in New York on June 22 at 2:00 p.m. ET. Both conference presentations will be webcast live. To access the... 
Printer Friendly Version
05/06/16Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, May 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 5, 2016 in Toronto, Ontario. A total of 18,005,470 common shares representing 68.82% of the Company's issued and outstanding common shares were voted in connection with the meeting. Shareholders voted in favour of all items ... 
Printer Friendly Version
05/05/16Cipher Pharmaceuticals Reports Q1 2016 Financial Results
-     Revenue increased 23% -     Delivered on multiple commercial and regulatory milestones -     Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May 5, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended March 31, 2016. Unless otherwise noted, all figures are in U.S. currency. "In the first quarter,... 
Printer Friendly Version
05/02/16Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream
Product candidate may have the potential to transform tattoo removal process MISSISSAUGA, ON, May 2, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has licensed the worldwide rights to develop and commercialize an investigational tattoo removal cream being developed at Dalhousie University in Halifax, Nova Scotia by Alec Falkenham, a PhD student in the Department of Pathology at Dalhousie University. The product candid... 
Printer Friendly Version
04/22/16Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting
MISSISSAUGA, ON, April 22, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2016 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 5, 2016. Q1 2016 CONFERENCE CALL WHEN: Thursday, May 5, 2016 at 8:30AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherph... 
Printer Friendly Version
04/22/16Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans
MISSISSAUGA, ON, April 22, 2016  /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Norm Evans, Chief Financial Officer, will be retiring from the Company. Mr. Evans will remain in his current role to ensure a smooth transition of responsibilities, and the Company has commenced a formal search process for a new CFO. "Norm has been an important part of Cipher's growth and success since 2007, and on behalf of the Board and all the... 
Printer Friendly Version
04/07/16Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
MISSISSAUGA, ON, April 7, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016. Ms. Crane has more than 30 years of experience in large global pharmaceutical companies and development-stage companies. She currently s... 
Printer Friendly Version
<< First | Previous | Next | Last >>